- LBT Innovations (LBT) says its sales momentum is improving as the US begins to reopen in full after the COVID-19 pandemic
- The medtech business’ access to US labs is improving, with sales executives now able to meet face-to-face as travel restrictions ease
- Meanwhile, the healthcare stock continues to advance the commercialisation of its APAS Independence technology
- LBT is aiming to appoint a US distributor for the microbiology tech between July and September this year
- Company shares are trading down 1.16 per cent at 8.5 cents per share
LBT Innovations (LBT) said sales momentum is improving as the US begins to reopen from the COVID-19 pandemic.
The medical technology business released a US commercial progress update on Monday, noting access to US labs is improving.
The company said its sales executives are finally able to meet face-to-face with clients after travel restrictions previously delayed these interactions.
The healthcare stock said the update was “encouraging” as it continues to advance the commercialisation of its APAS Independence technology.
LBT is aiming to appoint a US distributor for the microbiology tech between July and September this year.
It’s already signed a Master Product Agreement with AdventHealth Medical Group and also won a spot to showcase its APAS tech at the Vizient Innovative Technology Exchange.
“The ability to travel again in the US in recent weeks is really encouraging as there is no better way to showcase our technology and engage with potential customers than for our sales team to meet them in person in their labs,” CEO Brent Barnes said.
“We are pleased with our first agreement with AdventHealth and also the opportunity that will be provided to us at the highly regarded Vizient Technology Exchange.
“We remain confident of appointing a highly credentialled distributor for the APAS Independence in the United States in Q3 2021 and accelerating our sales traction once appointed.”
Company shares are trading down 1.16 per cent at 8.5 cents per share at 12:07 pm AEST.